Cannon Advisors’s Quest Diagnostics DGX Stock Holding History

Cannon Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-4,387	Closed	-$904K	–	111
2026 Q2	$904K	Buy	+4,387	New	+$861K	0.55%	45

Other funds holding DGX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Cannon Advisors's DGX Position: Q3 2026 in Review

Cannon Advisors sold out of Quest Diagnostics (DGX) in Q3 2026, closing a stake of 4,387 shares — an estimated $904K sold.

Cannon Advisors first reported a position in DGX in Q2 2026 and held it in 1 quarter. The position peaked at $904K in Q2 2026. 701 funds tracked by Wall St. Rank hold DGX as of Q3 2026.

Cannon Advisors reported no remaining Quest Diagnostics position as of Q3 2026 after selling out during the quarter.
Cannon Advisors sold 4,387 Quest Diagnostics shares in Q3 2026, an estimated $904K.
Cannon Advisors first reported a position in Quest Diagnostics in Q2 2026 and held it in 1 quarter.
Cannon Advisors's Quest Diagnostics position peaked at $904K in Q2 2026.
701 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.

Based on Cannon Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.